发布求助
文献互助 智能选刊 最新文献

Nihon Gan Chiryo Gakkai shi最新文献

筛选
英文 中文
[Examination of the effects of age on prognostic factors of squamous cell carcinoma of the uterine cervix]. [年龄对宫颈鳞状细胞癌预后影响因素的探讨]。
Nihon Gan Chiryo Gakkai shi Pub Date : 1990-08-20
S Kodama, S Honma, K Kanazawa, K Tanaka
{"title":"[Examination of the effects of age on prognostic factors of squamous cell carcinoma of the uterine cervix].","authors":"S Kodama,&nbsp;S Honma,&nbsp;K Kanazawa,&nbsp;K Tanaka","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The presence or absence of an association between age and prognostic factors of squamous cell carcinoma of the uterine cervix, including histologic cell type, depth of invasion, stromal reaction, CPL classification, and lymph node metastasis, was examined in 380 patients who had undergone radical hysterectomy. Age affected the rate of lymph node metastasis according to depth of invasion, and the metastasis rates in patients with invasion of 2/3 of the lateral side of the muscular layer (gamma type) in groups of patients in their 30s, 40s, 50s, and 60s were 40.0% (4/10), 59.3% (16/27), 36.7% (18/49), and 21.6% (8/37), respectively. Similarly, the metastasis rates in patients with invasion of the parametrium (delta type) in the above age groups were 100% (1/1), 72.7% (8/11), 46.4% (13/28), and 36.7% (11/30). Lymph node metastasis was significantly less in patients in their 60s than those in their 40s (gamma: p less than 0.01, delta: p less than 0.05). Moreover, 5-year survival rates of patients with lymph node metastasis (tested by Kaplan-Meier method) were 33.3% (N = 4), 65.0% (N = 15), 81.9% (N = 17), and 100% (N = 8) in groups of patients in their 30s, 40s, 50s, and 60s respectively, in the gamma type, and 45.0% (N = 8), 45.7% (N = 10), and 79.6% (N = 11) in groups of patients in their 40s, 50s, and 60s respectively, in the delta type. A significant difference was noted between the group of patients in their 60s and other age groups (gamma: p less than 0.01, delta: p less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)</p>","PeriodicalId":76232,"journal":{"name":"Nihon Gan Chiryo Gakkai shi","volume":"25 8","pages":"1579-86"},"PeriodicalIF":0.0,"publicationDate":"1990-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13383003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Chemotherapy for advanced and recurrent cancer patients--the effect of combination chemotherapy using cisplatin, peplomycin, mitomycin C, adriamycin, and 5-fluorouracil]. [晚期和复发癌症患者的化疗——顺铂、培霉素、丝裂霉素C、阿霉素和5-氟尿嘧啶联合化疗的效果]。
Nihon Gan Chiryo Gakkai shi Pub Date : 1990-08-20
Y Sato, H Tohma, T Shikama
{"title":"[Chemotherapy for advanced and recurrent cancer patients--the effect of combination chemotherapy using cisplatin, peplomycin, mitomycin C, adriamycin, and 5-fluorouracil].","authors":"Y Sato,&nbsp;H Tohma,&nbsp;T Shikama","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>According to the data obtained from the fundamental investigations using flow cytometry we designed the schedule of combination chemotherapy for solid cancer patients and we tried this therapy on 25 patients with non-curative, unresectable and recurrent cancers: 9 gastric, 5 colo-rectal, 3 esophageal, 3 pancreatic, 2 gall bladder, 2 lung and 1 breast cancer. The treatment was performed every 3 or 4 weeks as follows: CDDP 70 mg/m2 (d.i.), PEP 4 mg/m2 (i.v.) and MMC 4 mg/m2 (i.v.) on day 1, ADM 15 mg/m2 (i.v.) on day 4, and 5-Fu 250 mg/body (d.i.) every day. Among 22 patients evaluated completely, 1 complete response, 9 partial responses, 11 no changes, 1 progressive disease were obtained. The overall response rate was 45%. From the comparison of survival curves, survival rate was significantly better in patients responded to this therapy than in patients who did not respond to it (p less than 0.05). As for side effects, myelosuppression occurred in 19 patients (86%), increase of BUN and/or creatinine were observed in 3 patients (14%), increase of GOT and/or GPT were seen in 10 patients (45%), gastrointestinal symptoms and alopecia were observed in almost all patients, but all of these toxicity were transient and did not impede the continuous treatment.</p>","PeriodicalId":76232,"journal":{"name":"Nihon Gan Chiryo Gakkai shi","volume":"25 8","pages":"1565-70"},"PeriodicalIF":0.0,"publicationDate":"1990-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"12864644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Mass screening for uterine cancer during the last 10 years--its present situation and problems]. 【近10年大规模子宫癌筛查现状及问题】。
Nihon Gan Chiryo Gakkai shi Pub Date : 1990-08-20
K Taguchi, T Kushima, H Hosoda, J Higuchi
{"title":"[Mass screening for uterine cancer during the last 10 years--its present situation and problems].","authors":"K Taguchi,&nbsp;T Kushima,&nbsp;H Hosoda,&nbsp;J Higuchi","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>In Omagari city and five towns, 37,793 women were subjected to mass screening of uterine carcinoma from 1979 to 1988. The detection rate of uterine carcinoma was 0.058%. Initial screening rate was 41% 10 years ago, but in 1988, it was decreased to 18%. The peak age of the mass screening was 50-54 years old, but the carcinoma and dysplasia high degree were detected mostly in patients aged 60 years old or more. And the constitution of the age of mass screening in this study was inadequate for the screening of endometrial carcinoma. It is important to emphasize that older women (aged 60 or above) and nullipara should be encouraged to actively participate in the screening of cervical and endometrial carcinoma.</p>","PeriodicalId":76232,"journal":{"name":"Nihon Gan Chiryo Gakkai shi","volume":"25 8","pages":"1592-8"},"PeriodicalIF":0.0,"publicationDate":"1990-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13381659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[How to deal with equivocal subjects in statistical analysis of randomized controlled trials]. [随机对照试验统计分析中如何处理模棱两可的受试者]。
Nihon Gan Chiryo Gakkai shi Pub Date : 1990-08-20
N Hamajima, R Ohno
{"title":"[How to deal with equivocal subjects in statistical analysis of randomized controlled trials].","authors":"N Hamajima,&nbsp;R Ohno","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>In randomized controlled trials, it is likely that several subjects with atypical features are registered. In this paper, it was discussed from a statistical point of view how properly the subjects with the following atypical features could be dealt with; 1) subjects who were found to be not eligible for the trial after randomization, 2) subjects who did not receive the assigned regimen by the treatment protocol, 3) subjects whose outcome was ambiguous as the designated endpoint, and 4) subjects who were ambiguous whether to be regarded as censored cases. It was also emphasized that informations on equivocal subjects should be masked in the committee which is responsible for the statistical judgement. Plausible examples were added to assist the readers to understand the rules discussed here.</p>","PeriodicalId":76232,"journal":{"name":"Nihon Gan Chiryo Gakkai shi","volume":"25 8","pages":"1537-42"},"PeriodicalIF":0.0,"publicationDate":"1990-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13383001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Clinical study of preoperative radiotherapy of bladder cancer]. 膀胱癌术前放疗的临床研究
Nihon Gan Chiryo Gakkai shi Pub Date : 1990-07-20
H Shimada, K Imanaka, T Hashimura, S Hirota, K Yonezawa, T Soezima, K Izumiyama, M Kono, K Goji, M Hamami
{"title":"[Clinical study of preoperative radiotherapy of bladder cancer].","authors":"H Shimada,&nbsp;K Imanaka,&nbsp;T Hashimura,&nbsp;S Hirota,&nbsp;K Yonezawa,&nbsp;T Soezima,&nbsp;K Izumiyama,&nbsp;M Kono,&nbsp;K Goji,&nbsp;M Hamami","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>From May 1982 to Nov. 1987, 33 patients with bladder carcinoma were treated with preoperative radiotherapy (20 Gy/5fr) and total cystectomy. The over all 3-year survival rate was 70%. For T1 and T2, 3-year survival rate was 100%, but only 55% and 0% for T3 and T4 respectively. In 23 out of 33 patients, preoperative T-stage was confirmed by TUR-BT. Down-Staging was recognized in 7 out of 23 patients (30%). They were 0 out of 1 patients for Tcis (0%), 2 of 3 for T1 (67%), 3 of 6 for T2 (50%), 2 of 11 for T3 (18%) and 0 of 2 for T4 (0%). This protocol of preoperative radiotherapy is thought to be favorable for T1 and T2 bladder carcinoma, but inadequate for T3 and T4 tumors. Consequently, it is considered that higher dose radiotherapy and postoperative chemotherapy are necessary for T3 and T4 bladder carcinoma.</p>","PeriodicalId":76232,"journal":{"name":"Nihon Gan Chiryo Gakkai shi","volume":"25 7","pages":"1385-90"},"PeriodicalIF":0.0,"publicationDate":"1990-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13365423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Clinical value of a new serum tumor marker CA602 in ovarian cancers]. [新型血清肿瘤标志物CA602在卵巢癌中的临床价值]。
Nihon Gan Chiryo Gakkai shi Pub Date : 1990-07-20
M Suzuki, I Sekiguchi, M Ohwada, I Aida, T Tamada
{"title":"[Clinical value of a new serum tumor marker CA602 in ovarian cancers].","authors":"M Suzuki,&nbsp;I Sekiguchi,&nbsp;M Ohwada,&nbsp;I Aida,&nbsp;T Tamada","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>We investigated the usefulness of CA602, a newly developed serum tumor marker, for ovarian cancer. When the cut-off value was set at 60 U/ml, the overall positive rate of this marker in ovarian cancer was 92%, a slightly high rate relative to CA125 measured at the same time (88%). Considering tumor histology, CA602 revealed a high positive rate of 100% in serous adenocarcinoma, whereas the positive rate was 67% in mucinous adenocarcinoma. However, the positive rate was relatively high in benign diseases such as endometrial cysts (64%) and benign ovarian tumors (29%). It is concluded that CA602 is a tumor marker with low specificity and high sensitivity in general. The definite correlation between CA602 and CA125 in ovarian tumors (R = 0.96) suggests that these markers have certain similarities. Thus, CA602 may be a useful serum tumor marker for ovarian cancer as a substitute for CA125.</p>","PeriodicalId":76232,"journal":{"name":"Nihon Gan Chiryo Gakkai shi","volume":"25 7","pages":"1454-60"},"PeriodicalIF":0.0,"publicationDate":"1990-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13324027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[A case report of hemolytic uremic syndrome (HUS) induced by antineoplastic agents]. [抗肿瘤药物致溶血性尿毒症综合征1例报告]。
Nihon Gan Chiryo Gakkai shi Pub Date : 1990-07-20
H Anai, Y Okada, K Okubo, D Korenaga, Y Maehara, K Sugimachi, Y Ohi
{"title":"[A case report of hemolytic uremic syndrome (HUS) induced by antineoplastic agents].","authors":"H Anai,&nbsp;Y Okada,&nbsp;K Okubo,&nbsp;D Korenaga,&nbsp;Y Maehara,&nbsp;K Sugimachi,&nbsp;Y Ohi","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>An autopsy case of hemolytic uremic syndrome after treatment with antineoplastic agents for advanced gastric carcinoma is reported. A 70 year-old woman underwent partial gastrectomy for gastric carcinoma on April 16, 1987 (P0H0S2N4, Stage IV). She was treated with Mitomycin C (MMC), UFT, OK-432 and PSK as post operative chemotherapy. Total doses were 60 mg of MMC, 33.9 g of UFT, 55 KE of OK-432 and (507 g) of PSK. She suffered from occult blood in urine in September 1987, thrombocytopenia and anemia in October, edema and hypertension in November and died due to acute renal failure and pulmonary failure on December 5, 1987. It seemed that the cause of death was hemolytic uremic syndrome induced by antineoplastic agents.</p>","PeriodicalId":76232,"journal":{"name":"Nihon Gan Chiryo Gakkai shi","volume":"25 7","pages":"1487-91"},"PeriodicalIF":0.0,"publicationDate":"1990-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13275537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Local injection of high-dose CDDP to the advanced gynecological cancer]. 【局部注射大剂量CDDP治疗晚期妇科肿瘤】。
Nihon Gan Chiryo Gakkai shi Pub Date : 1990-07-20
K Hashii, A Takahashi, T Kanto, M Ukita, I Tateyama, S Natsuyama, T Mori
{"title":"[Local injection of high-dose CDDP to the advanced gynecological cancer].","authors":"K Hashii,&nbsp;A Takahashi,&nbsp;T Kanto,&nbsp;M Ukita,&nbsp;I Tateyama,&nbsp;S Natsuyama,&nbsp;T Mori","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>We investigated the efficacy of local injection of high-dose CDDP. The subjects were 16 patients with advanced gynecological cancer or tumor recurrence, in whom systemic administration of CDDP was inadvisable because of advanced age or associated complications (12 cases of cervical carcinoma, 2 cases of endometrial carcinoma, 1 case of ovarian carcinoma, and 1 case of vulvar carcinoma). In 14 cases, CDDP was injected locally to the tumor mass, using a single dose of 50-300 mg. In 2 cases, a single dose of 10-20 mg of CDDP was infused into the uterine cavity. The effects of the therapy were evaluated by cytodiagnosis, tumor markers, CT, and performance status. In all cases, an antitumor effect was noted, and seven subjects survived for at least 24 months following these therapy with CDDP. One patient developed vesicovaginal and rectovaginal fistulae after local injection of CDDP following high-dose radiotherapy. We investigated the plasma concentrations of free and total platinum after CDDP application with doses from 60-200 mg/body. Plasma concentrations showed a biphasic pattern (phase alpha and phase beta), and the peak plasma concentration of CDDP was lower than that following intravenous administration of the same dose. From these results, it was suggested that a large dose of CDDP can be injected into the tumor tissue itself and the surrounding tissue with comparatively few side effects. It will be possible to administer large dose of CDDP in this way to the terminal patients to whom there is currently no other appropriate method of treatment. The performance status of our subjects was improved, and we expect that wider use of this method will improve the quality of life for end-stage patients.</p>","PeriodicalId":76232,"journal":{"name":"Nihon Gan Chiryo Gakkai shi","volume":"25 7","pages":"1472-81"},"PeriodicalIF":0.0,"publicationDate":"1990-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13365380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Radiation therapy for prostatic cancer]. 前列腺癌的放射治疗。
Nihon Gan Chiryo Gakkai shi Pub Date : 1990-07-20
T Teshima, M Chatani, T Inoue, M Usami, T Kotake
{"title":"[Radiation therapy for prostatic cancer].","authors":"T Teshima,&nbsp;M Chatani,&nbsp;T Inoue,&nbsp;M Usami,&nbsp;T Kotake","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>From February 1979 through May 1988, a total of 26 patients with adenocarcinoma of the prostate were treated with radiation therapy for the primary site. The actuarial 5-year survival rate was 59% for 14 patients with Stage C or less disease (A; 1 case, B; 2 cases, and C; 11 cases), and 10% for 12 patients with Stage D. The logrank test showed significant difference between these two groups (p less than 0.007). Rectal radiation injuries occurred in 2 cases (8%) at 7 months (grade I) and 6 months (grade II), respectively. From the analysis of local control and complication, optimum radiation dose ranged from 64.8 Gy to 68.4 Gy (TDF 100-106). In addition, optimum boost radiation field size with rotation technique (after whole pelvic irradiation of 40-45 Gy with anteroposterior opposing fields) ranged from 30 to 48 cm2.</p>","PeriodicalId":76232,"journal":{"name":"Nihon Gan Chiryo Gakkai shi","volume":"25 7","pages":"1404-9"},"PeriodicalIF":0.0,"publicationDate":"1990-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13365426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Studies on intracellular kinetics of ara-C triphosphate in HL-60, human leukemia cells in relation to reasonable administration of ara-C]. [人白血病HL-60细胞内ara-C三磷酸动力学与ara-C合理给药的关系研究]。
Nihon Gan Chiryo Gakkai shi Pub Date : 1990-07-20
K Kamiya, M Uchida, T Ueda, T Nakamura
{"title":"[Studies on intracellular kinetics of ara-C triphosphate in HL-60, human leukemia cells in relation to reasonable administration of ara-C].","authors":"K Kamiya,&nbsp;M Uchida,&nbsp;T Ueda,&nbsp;T Nakamura","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>To study the pharmacokinetics of 1-beta-D-arabinofuranosylcytosine (ara-C), which is one of the main drugs used in chemotherapy for acute leukemia, its intracellular metabolism was investigated using HL-60 cells derived from human acute non-lymphocytic leukemia. The concentration of the drug and its metabolites in the cells were serially determined and the following results were obtained. 1) The uptake of ara-C into HL-60 cell (1 X 10(7)/ml) was very rapid when they were incubated with 2 microM ara-C. The total intracellular ara-C content per 10(9) cells exceeded the ara-C concentration in the extracellular fluid at about 7 minutes after the start of incubation. It reached about 4 times higher than the extracellular concentration after 60 minutes. 2) Conversion of ara-C to the active form, ara-CTP, was also rapid. The intracellular concentration of ara-CTP was about 3 times higher than the ara-C concentration in the extracellular fluid after incubation for 60 minutes. 3) Total accumulation of ara-C in the cells was dependent on the extracellular ara-C concentration up to a concentration of 100 microM. The production of ara-CTP occurred in such a way that, when the extracellular ara-C concentration was lower than 10 microM, more than 90% of the uptake of ara-C was converted to ara-CTP, while at concentrations above 10 microM the efficiency at production (the ratio of total ara-C to ara-CTP production) was decreased. The maximum intracellular ara-CTP concentration was estimated to reach to 45 microM.(ABSTRACT TRUNCATED AT 250 WORDS)</p>","PeriodicalId":76232,"journal":{"name":"Nihon Gan Chiryo Gakkai shi","volume":"25 7","pages":"1419-27"},"PeriodicalIF":0.0,"publicationDate":"1990-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13365428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信